Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter March 12, 2019

Association study of the CTH 1364 G>T polymorphism with coronary artery disease in the Greek population

  • Efstathia Giannakopoulou , Fotios Konstantinou , Georgia Ragia , Zisis Gerontitis , Anna Tavridou , Andreas Papapetropoulos , Dimitrios Mikroulis and Vangelis G. Manolopoulos EMAIL logo

Abstract

Background

Cystathionine γ-lyase enzyme, which is encoded by the CTH gene, is responsible for hydrogen sulfide (H2S) production in the endothelium. The CTH 1364 G>T polymorphism may alter the CTH expression and H2S bioavailability, thus leading to atherosclerosis and coronary artery disease (CAD). We examined the potential association of the CTH 1364 G>T polymorphism with CAD.

Methods

The CTH 1364 G>T polymorphism was determined in 178 coronary artery bypass grafting (CABG) patients and 156 non-atherosclerotic controls of Greek Caucasian origin using the PCR–RFLP method.

Results

No significant difference in the frequency of the CTH 1364 G>T genotypes (p = 0.281) and alleles (p = 0.265) was found between the CABG patients and controls. After conducting stratification according to sex, analysis showed a numerical difference in the CTH 1364 TT genotype frequency in female participants that did not reach statistical significance (16.3% and 8.5% in the CABG and controls, respectively, p = 0.26). The frequency of the CTH 1364 TT genotype between the male CABG patients and controls did not differ (p = 0.507).

Conclusions

The CTH 1364 G>T polymorphism was not associated with CAD in the studied population. However, interestingly, a higher – if not significantly so – CTH 1364 TT genotype frequency was present in female CABG patients compared with female controls. Larger studies are necessary to conclude on the potential overall or gender-driven association between CTH 1364 G>T gene polymorphism and CAD.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: The study has been co-financed by the European Union (European Social Fund – ESF) and Greek national funds through the Operational Program ‘Education and Lifelong Learning’ of the National Strategic Reference Framework (NSRF) - Research Funding Program: Thales. (‘Hydrogen sulfide a new endogenous regulator of angiogenesis: signaling, physiology/pathophysiology and development of pharmacological inhibitors’).

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

[1] Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y, Ali F. Atherosclerotic cardiovascular disease: a review of initiators and protective factors. Inflammopharmacology 2016;24:1–10.10.1007/s10787-015-0255-ySearch in Google Scholar PubMed

[2] Pan LL, Qin M, Liu XH, Zhu YZ. The role of hydrogen sulfide on cardiovascular homeostasis: an overview with update on immunomodulation. Front Pharmacol 2017;8:686.10.3389/fphar.2017.00686Search in Google Scholar PubMed PubMed Central

[3] Marshall T, Dorman D, Gardner D, Adeshina F. Provisional Advisory Levels (PALs) for hydrogen sulfide (H2S). Inhal Toxicol 2009;21(Suppl 3):56–72.10.3109/08958370903202812Search in Google Scholar PubMed

[4] Wang R, Szabo C, Ichinose F, Ahmed A, Whiteman M, Papapetropoulos A. The role of H2S bioavailability in endothelial dysfunction. Trends Pharmacol Sci 2015;36:568–78.10.1016/j.tips.2015.05.007Search in Google Scholar PubMed PubMed Central

[5] Mani S, Li H, Untereiner A, Wu L, Yang G, Austin RC, et al. Decreased endogenous production of hydrogen sulfide accelerates atherosclerosis. Circulation 2013;127:2523–34.10.1161/CIRCULATIONAHA.113.002208Search in Google Scholar PubMed

[6] Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008;322:587–90.10.1126/science.1162667Search in Google Scholar PubMed PubMed Central

[7] Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiological reviews 2012;92:791–896.10.1152/physrev.00017.2011Search in Google Scholar PubMed

[8] Wang J, Hegele RA. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). Hum Genet 2003;112:404–8.10.1007/s00439-003-0906-8Search in Google Scholar PubMed

[9] Huezo-Diaz Curtis P, Uppugunduri CR, Muthukumaran J, Rezgui MA, Peters C, Bader P, et al. Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation. Pharmacogenomics J 2016;18:64–69.10.1038/tpj.2016.65Search in Google Scholar PubMed PubMed Central

[10] Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis GV, et al. Renin-angiotensin-aldosterone system gene polymorphisms in coronary artery bypass graft surgery patients. Journal of the renin-angiotensin-aldosterone system: JRAAS 2010;11:136–45.10.1177/1470320310361742Search in Google Scholar PubMed

[11] Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis GV, et al. Endothelial nitric oxide synthase gene polymorphisms -786T > C and 894G > T in coronary artery bypass graft surgery patients. Human genomics 2010;4:375–83.10.1186/1479-7364-4-6-375Search in Google Scholar PubMed PubMed Central

[12] Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281–357.10.1201/b17072-61Search in Google Scholar

[13] Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Diab Vasc Dis Res 2014;11:133–73.10.1177/1479164114525548Search in Google Scholar PubMed

[14] Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110:e340–437.10.1161/circ.110.14.e340Search in Google Scholar

[15] Iordanidou M, Tavridou A, Petridis I, Kyroglou S, Kaklamanis L, Christakidis D, et al. Association of polymorphisms of the serotonergic system with smoking initiation in Caucasians. Drug Alcohol Depend 2010;108:70–6.10.1016/j.drugalcdep.2009.11.015Search in Google Scholar PubMed

[16] Misailidis G, Ragia G, Ivanova DD, Tavridou A, Manolopoulos VG. Gene-gene interaction of mu-opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect. Drug Metab Pers Ther 2015;30:129–35.Search in Google Scholar

[17] Wang J, Huff AM, Spence JD, Hegele RA. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration. Clin Genet 2004;65:483–6.10.1111/j.1399-0004.2004.00250.xSearch in Google Scholar PubMed

[18] Sen U, Givvimani S, Abe OA, Lederer ED, Tyagi SC. Cystathionine beta-synthase and cystathionine gamma-lyase double gene transfer ameliorate homocysteine-mediated mesangial inflammation through hydrogen sulfide generation. Am J Physiol Cell Physiol 2011;300:C155–63.10.1152/ajpcell.00143.2010Search in Google Scholar PubMed PubMed Central

[19] Giannakopoulou E, Konstantinou F, Ragia G, Tavridou A, Karaglani M, Chatzaki E, et al. Epigenetics-by-sex interaction for coronary artery disease risk conferred by the cystathionine gamma-lyase gene promoter methylation. Omics 2017;21:741–8.10.1089/omi.2017.0149Search in Google Scholar PubMed

[20] Kraus JP, Hasek J, Kozich V, Collard R, Venezia S, Janosikova B, et al. Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies. Mol Genet Metab 2009;97:250–9.10.1016/j.ymgme.2009.04.001Search in Google Scholar PubMed PubMed Central

[21] Tzeng JY, Lu W, Hsu FC. Gene-level pharmacogenetic analysis on survival outcomes using gene-trait similarity regression. Ann Appl Stat 2014;8:1232–55.10.1214/14-AOAS735Search in Google Scholar

[22] Li Y, Zhao Q, Liu XL, Wang LY, Lu XF, Li HF, et al. Relationship between cystathionine gamma-lyase gene polymorphism and essential hypertension in Northern Chinese Han population. Chin Med J (Engl) 2008;121:716–20.10.1097/00029330-200804020-00011Search in Google Scholar

[23] Rajpal S, Katikaneni P, Deshotels M, Pardue S, Glawe J, Shen X, et al. Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease. Redox Biol 2018;15:480–9.10.1016/j.redox.2018.01.007Search in Google Scholar PubMed PubMed Central

Received: 2018-10-25
Accepted: 2019-01-23
Published Online: 2019-03-12

©2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/dmpt-2018-0033/html
Scroll to top button